Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bergman

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Gynecologic Oncology|November 7, 2025
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191]Premal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
Gynecologic Oncology|June 3, 2025
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancerPremal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
American Journal of Medical Genetics. Part A|March 29, 2023
Extending the phenotypes associated with TRIO gene variants in a cohort of 25 patients and review of the literatureGabriella Gazdagh, David Hunt, Anna Maria Cueto Gonzalez, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Gynecologic Oncology|November 7, 2025
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191]Premal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
Gynecologic Oncology|June 3, 2025
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancerPremal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
American Journal of Medical Genetics. Part A|March 29, 2023
Extending the phenotypes associated with TRIO gene variants in a cohort of 25 patients and review of the literatureGabriella Gazdagh, David Hunt, Anna Maria Cueto Gonzalez, et al.
Pageof 14